Medpace demonstrates strong financial performance and growth in the CRO market, despite facing challenges in the short term.

This was the stock's second consecutive day of gains.

Morgan Stanley analyst Tejas Savant lowered the firm’s price target on Charles River (CRL) to $184 from $220 and keeps an Equal Weight rating ...

Charles River Laboratories Financial Overview And Stock Metrics ...

Request To Download Free Sample of This Strategic Report @ Driving Forces Behind the Growth: The robust growth of the Asia Pacific pharmaceutical analytical testing outsourcing market is propelled by ...

North America bioprocess technology market is projected to grow by 13.3% annually in the forecast period and reach $29.68 billion by 2033. The growth is driven an increasing prevalence of chronic ...

Charles River is shuttering its pathology facility in Durham, North Carolina, after determining the site “is not a strategic ...

Shares of Charles River Laboratories International Inc. CRL shed 1.91% to $161.62 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX ...

Charles River Laboratories is permanently closing its pathology facility in Durham, NC, after determining it is no longer “a ...

Members of Congress and animal rights advocates believe the Department of Government Efficiency could end animal testing ...